BridgeBio Pharma Inc Long-term Investment Intensity
BridgeBio Pharma Inc long-term investment intensity. BridgeBio Pharma Inc (BBIO) has a Long-term Investment Intensity of 4.5% as of June 2026. Long-term investments of $55.09 Million represent 4.5% of total assets of $1.22 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Read BBIO liabilities breakdown for a breakdown of total debt and financial obligations.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Long-term Investment Intensity of BridgeBio Pharma Inc (2018–2025)
Long-term investment intensity of BridgeBio Pharma Inc from 2018 to 2025. This chart shows how BridgeBio Pharma Inc's Long-term Investment Intensity has evolved across 6 annual periods from 2018 to 2025. As of June 2026, the intensity stands at 4.5%, reflecting long-term investments of $55.09 Million against total assets of $1.22 Billion USD.
BridgeBio Pharma Inc Long-term Investment Intensity by Year (2018–2025)
BridgeBio Pharma Inc long-term investment intensity by year from 2018 to 2025. The table below presents the year-by-year Long-term Investment Intensity for BridgeBio Pharma Inc from 2018 to 2025, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see BBIO asset base.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 8.5% | $79.97 Million | $936.02 Million | ▼ -7.1 pp |
| 2024 | 15.6% | $143.75 Million | $919.34 Million | ▲ +8.6 pp |
| 2022 | 7.0% | $43.65 Million | $623.04 Million | ▲ +2.2 pp |
| 2021 | 4.9% | $49.15 Million | $1.01 Billion | ▼ -0.1 pp |
| 2019 | 4.9% | $31.14 Million | $631.68 Million | ▲ +1.3 pp |
| 2018 | 3.7% | $17.05 Million | $464.94 Million | — |